Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

The Study of Drotrecogin Alfa (Activated) in Adult Patients With Severe Sepsis at a Low Risk of Death

Phase 3

Completed

Conditions: Sepsis

Interventions: Drug: Placebo
Drug: Drotrecogin alfa (activated)

First Posted Date: 2007-12-06

Last Posted Date: 2007-12-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2640

Registration Number: NCT00568737

Locations: 🇫🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Gleize, France

Multi-Country Observational Study to Collect the Frequency of Sexual Dysfunction With Antidepressant Treatment, Either With SSRIs or Duals at 8 Weeks and 6 Months

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: SSRIs
Drug: Dual antidepressants

First Posted Date: 2007-11-21

Last Posted Date: 2009-07-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1626

Registration Number: NCT00561509

Locations: 🇦🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Dubai, United Arab Emirates

Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Glargine
Drug: Insulin Lispro Protamine Suspension

First Posted Date: 2007-11-19

Last Posted Date: 2011-01-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 339

Registration Number: NCT00560417

Locations: 🇵🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yabucoa, Puerto Rico

A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide

Phase 4

Completed

Conditions: Osteoporosis, Postmenopausal

Interventions: Drug: teriparatide

First Posted Date: 2007-11-14

Last Posted Date: 2011-11-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 35

Registration Number: NCT00557310

Locations: 🇨🇦
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Vancouver, British Columbia, Canada

A Study for the Treatment of Diabetic Peripheral Neuropathic Pain

Phase 3

Completed

Conditions: Diabetic Neuropathies

Interventions: Drug: Duloxetine hydrochloride - 60 mg
Drug: Duloxetine hydrochloride - 40 mg
Drug: placebo

First Posted Date: 2007-11-01

Last Posted Date: 2010-04-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 339

Registration Number: NCT00552175

Locations: 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT -5 hours, ETS), or speak with your personal physician, Okayama, Japan
🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Toyama, Japan

24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine

Phase 4

Completed

Conditions: Type 2 Diabetes

Interventions: Drug: Lispro mix 75/25
Drug: Glargine

First Posted Date: 2007-10-31

Last Posted Date: 2010-10-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 15

Registration Number: NCT00551538

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Lispro Mix 25 vs. Glargine in Type 2 Diabetics

Phase 3

Completed

Conditions: Diabetes Mellitus Type 2

Interventions: Drug: Glargine
Drug: Insulin lispro mix 25

First Posted Date: 2007-10-31

Last Posted Date: 2007-10-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 53

Registration Number: NCT00551356

Locations: 🇲🇽
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Mexico City, Mexico

Enzastaurin and Bevacizumab in Treating Patients With Locally Advanced or Metastatic Cancer

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2007-10-30

Last Posted Date: 2013-05-15

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 42

Registration Number: NCT00550927

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: pemetrexed
Drug: erlotinib

First Posted Date: 2007-10-29

Last Posted Date: 2013-02-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 247

Registration Number: NCT00550173

Locations: 🇬🇧
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Manchester, United Kingdom

An Observational Study Evaluating Patient Satisfaction and Quality of Life Associated With Switching Insulin

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Analog or Human Insulin

First Posted Date: 2007-10-26

Last Posted Date: 2010-03-16

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2459

Registration Number: NCT00549887

Locations: 🇹🇷
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Konya, Turkey

Home Terms & Conditions Privacy Policy